StockData
ALZNNasdaqPharmaceutical PreparationsFiscal year ends April 30

Alzamend Neuro, Inc.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 10, 2026
$1.33+0.03 (+2.31%)

Close on Oct 19, 2026

Market cap
$5.96M
P/E (TTM)
–
Dividend yield
–

Alzamend Neuro, Inc. revenue by segment

AnnualQuarterlyTTM

No segment breakdown reported

Alzamend Neuro does not break out revenue by segment, region or product in the tagged data of its filings for this period type.